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Summary 
Objectives:  To determine the magnitude, risk factors and causes of premature 
mortality associated with epilepsy in low and middle income countries (LMIC).  
Methods:  We conducted a systematic search of the literature reporting mortality 
and epilepsy in the World Bank-defined LMIC. We assessed the quality of the 
studies based upon the representativeness, ascertainment of cases, diagnosis, and 
mortality and extracted data on the standardized mortality ratio (SMR), mortality rate, 
and incidence of death in epilepsy. We examined the risk factors for death and 
reviewed the causes of death.   
Results:  The annual mortality rate was estimated at 19.8 (range 9.7-45.1) deaths 
per 1000 people with epilepsy with a weighted median SMR of 2.6 (range 1.3-7.2) 
among higher-quality population-based studies. Clinical cohort studies yielded 7.1 
(range 1.6-25.1) deaths per 1000 people. The weighted median SMRs were 5.0 in 
males and 4.5 in females; relatively higher SMRs within studies were measured 
among children and adolescents, those with symptomatic epilepsies, and those 
reporting less adherence to treatment. The main causes of death in people with 
epilepsy living in LMICs include those directly attributable to epilepsy, which yield a 
mean proportional mortality ratio (PMR) of 27.3% (range 5%-75.5%) derived from 
population-based studies. These direct causes comprise status epilepticus, with 
reported PMRs ranging from 5%-56.6%, and sudden unexpected death in epilepsy, 
with reported PMRs ranging from 1%-18.9%. Important causes of mortality indirectly 
related to epilepsy include drowning, head injury, and burns. 
Significance:  Epilepsy in LMIC has a significantly greater premature mortality, as in 
high-income countries, but in LMIC the excess mortality is more likely to be 
associated with causes attributable to lack of access to medical facilities such as 
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status epilepticus, and preventable causes such as drowning, head injuries and 
burns. This excess premature mortality could be substantially reduced with 
education about the risk of death and improved access to treatments, including 
AEDs.   
 
Keywords: Seizures, convulsions, death, case fatality, developing countries, 
resource-poor countries, premature mortality  
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Introduction 
Standardized mortality in people with epilepsy in high-income countries (HIC) is 
estimated to be up to 4 to 15 times higher than the general population in community-
based studies and selected high-risk populations, respectively.1; 2 Comparable 
estimates of mortality in epilepsy in low- and middle-income countries (LMIC) are 
scarce, because vital registration of deaths is incomplete or absent in most 
countries, and many studies examining the risk of premature mortality in people with 
epilepsy in LMIC have methodological limitations. 
 Worldwide, approximately 80% of those with epilepsy live in LMIC.3; 4 The estimated 
overall incidence of epilepsy is also higher in LMIC than in HIC (incidence rate ratio: 
1.8, 95% CI 1.3–2.5).5 The high prevalence and incidence of epilepsy in LMIC is 
most likely associated with higher incidence of adverse perinatal events, head 
injuries, and parasitic infections.4; 6-10 
Some studies in LMIC7; 11; 12 have suggested that mortality in epilepsy is higher than 
in HIC.2  Higher mortality, whether comparing populations with and without epilepsy 
or populations of people with epilepsy in LMIC and HIC, can be described by relating 
age-specific mortality rates, most commonly expressed as standardized mortality 
ratios (SMR; Supporting Table 1B).  In effect, an elevated SMR in a population 
indicates excess premature mortality, i.e., a higher proportion of deaths occurring at 
earlier ages, relative to the comparison population.  Findings of relative excess 
mortality in LMIC may be attributed to the selection of studies in areas endemic with 
specific causes, selection of higher-risk cohorts to follow, or lack of access to 
comprehensive treatment.6 The epilepsy treatment gap (defined as the proportion of 
people with epilepsy who either have not accessed biomedical services or are not on 
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treatment with anti-epileptic drugs [AEDs] or are receiving inadequate treatment9) is 
more than 75% in LMIC, compared with less than 10% in HIC.10 The large treatment 
gap may increase mortality from complications such as status epilepticus, accidents 
including burns and drowning, and sudden unexpected death in epilepsy (SUDEP). 
We conducted a systematic review to estimate the magnitude of premature mortality 
associated with epilepsy in LMIC, and to identify the risk factors and causes of death 
among people with epilepsy. A companion review focuses on mortality in high-
income countries.13 
 
Methods 
Literature search.  We searched the Medline, EMBASE, and LILACS databases with 
terms in the following three categories: 
 epilepsy, seizure, or convulsions 
 mortality, death, or SUDEP 
 low-income countries, middle-income countries, developing countries, resource-poor 
countries, Africa, Asia, China, India, "Latin America," "Central America," or "South 
America"  
We included only reports indexed with at least one term in each of the three 
categories, and restricted our search to reports on human subjects from LMIC as 
defined by the World Bank.14,*  The search period was from 1990 to 28th February 
2014. We used the criteria for the diagnosis of epilepsy suggested by the 
                                                        
* Low-income economies in 2014 were those with annual gross national incomes (GNI) per capita of $1,045 
or less, while middle-income economies were those with GNI per capita ranging from $1,046 to 
$12,735.  The country income categories for studies included in this report are indicated in Tables 1 
and 2. 
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International League Against Epilepsy (ILAE) for epidemiological studies, originally in 
199315 and confirmed in 201016 and 2011.17  
Two reviewers (FL and CRN) evaluated the retrieved citations in a two-stage 
process. In the first stage they independently reviewed the titles and available 
abstracts to identify potentially relevant reports meriting full review (Figure 1). The 
reviewers compared their selections and resolved the list of publications to arrive at 
a single list for the second stage of analysis. In the second stage they reviewed the 
full papers and assessed whether the articles met the inclusion criteria below. For 
those meeting these criteria, they extracted the measures of mortality, risk factors, 
and causes of death. 
Inclusion criteria.  Original reports of mortality among people with epilepsy in LMIC, 
derived from general populations, clinical cohorts (hospital- or treatment program-
based), and case-control studies, were included. Studies that did not report 
quantitative estimates of mortality in epilepsy were excluded. 
Data extraction. Data on the epilepsy were extracted according to ILAE guidelines, in 
particular age at onset, seizure type, and the underlying etiology.17 Age at onset, i.e., 
first occurrence of unprovoked seizure, helps identify epilepsy syndromes. Three 
main categories of epilepsy/seizure type as classified by ILAE (generalized, focal, 
and undetermined) were identified.16; 17 The ILAE proposed three main categories of 
etiology: genetic, structural/metabolic, and unknown causes.16; 17 Epilepsy etiology is 
classified as genetic when genetic defects are the known or presumed to be prime 
cause of the disease (including epilepsies formerly known as idiopathic). 
Structural/metabolic causes (formerly known as symptomatic epilepsies) are 
considered when a structural lesion or metabolic condition is known to predispose to 
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epilepsy. It was expected that some studies would still report earlier epilepsy etiology 
categories as idiopathic, symptomatic, and cryptogenic (now termed unknown).18 
Estimates of mortality were extracted from the measures reported in the papers 
which included case fatality ratio (CFR), proportional mortality ratio (PMR), mortality 
rate (MR), and standardized mortality ratio (SMR) according to standard definitions 
(Supporting Table 1B).19 Deaths were categorized occurring: (i) as a direct 
consequence of epilepsy or seizures (i.e. status epilepticus, or SUDEP); (ii) as 
indirect causes (i.e., accidents due seizures—such as falls, burns, or drowning—or 
drug reactions to AEDs); (iii) as unrelated to epilepsy, or (iv) as undetermined (i.e. 
cause of death not ascertained). The definitions and classification of SUDEP are 
mainly consistent with the earlier recommendations,20 which have been updated 
since publication of most the studies we reviewed.21 
Quality of studies.  The reviewers employed quality assessment criteria for studies of 
mortality in epilepsy that included the following five elements classified by ILAE’s 
Commission on Epidemiology Task Force on the Burden of Mortality (Supporting 
Table 1A). These address the most important design features of epidemiologic 
studies of epilepsy, which we employed in preference to less specific conventional 
evaluation checklists proposed for observational studies.22 
 Representativeness of the study population.  Provides the basis of 
generalizability of the study findings. Studies conducted in clinical settings or 
untreated populations may not be representative of entire populations of 
people with epilepsy. 
 Accuracy of diagnosis of epilepsy.  Evaluates methods employed to diagnose 
cases of epilepsy; if quantifiable, can be expressed as a positive predictive 
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value. The use of the case definition provided by ILAE (at least two 
unprovoked seizures) and diagnosis by trained neurologists is a reference 
standard that may reduce the number of false positives and negatives. 
 Epilepsy case ascertainment.  Evaluates completeness (sensitivity) of 
methods employed to screen the population for cases of epilepsy. This is 
important in population-based studies of epilepsy prevalence or incidence. A 
door-to-door survey is thought to generate an optimum number of cases in 
screening of a community. 
 Mortality ascertainment.  Evaluates the completeness of identifying death 
occurrence in a cohort or population of people with epilepsy. This depends 
upon the proportion of people with epilepsy followed until death or end of the 
study. Short follow-up of individuals, high migration patterns and loss to 
follow-up are critical issues in establishing mortality rates. 
 Accuracy of cause of death. Evaluates the validity of cause-of-death 
determinations, especially for causes of interest associated with epilepsy. 
Accurate determination of the cause of death is essential to determine the 
proportion of deaths directly or indirectly related to epilepsy. Autopsies are the 
reference standard, but are rarely performed in LMICs. Verbal autopsies are 
most commonly used in LMIC23-25. 
A scale with five items was developed to score the quality of studies with respect to 
each quality measure listed above. The scoring of each item was generated from 4-5 
sub-items, each with 5 points, with a total score ranging from 0 to 20 (Supporting 
Table 1A). The total score of the quality was the sum of scores of each quality item, 
with 100 representing the highest quality. 
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Statistical analysis.  Total, median, and range were used to generate summary 
measures of mortality across studies. We disaggregated the estimates by study 
designs (population-based vs. clinical cohort), sex, type of seizure, etiology, and 
other risk factors. Summary estimates were also identified as reported, whether 
SMRs, PMRs, or MRs. If not reported as such, we calculated CFRs and MRs when 
the reports provided sufficient information to allow this. Standard definition of 
summary estimates can be found in Supporting Table 1B. 
We also examined heterogeneity statistics, which measure the extent to which SMRs 
vary between studies, including the I2 statistic, which is the percentage of between-
study heterogeneity that is explained by variability in the exposure effect on mortality 
relative to sampling error26. Heterogeneity statistics are crucial in deciding whether 
summary measure of SMR estimates from studies can be estimated.  
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Results 
Search results.  Results of the systematic search are provided in Figure 1. A total of 
17 articles met inclusion criteria, among which one article included reports from 4 
sites.27 and two articles reported separate findings from the same cohort.28; 29 Thus, 
the articles contained 12 reports of findings from population-based cohorts7; 8; 27; 29-35 
and 8 reports from clinical cohorts.12; 27; 36-41 South America provided 8 studies,8; 27; 34; 
36-40 Asia 6 studies,7; 27-29; 33; 41 and Africa 6  studies.12; 27; 30-32; 35. Nine studies were 
conducted in rural populations only,12; 27; 29-35 6 in urban only,7; 8; 27; 38; 41 and 5 in both 
urban and rural populations.27; 36; 37; 39; 40  
Quality of studies.  Supporting Table 2 provides summary characteristics of 
population-based studies, all of which included all ages. Population-based studies 
were mainly of good quality, where 7 out of 12 studies had a quality score of ≥80% 
(Table 2).7; 8; 27; 30; 31; 34; 35 Door-to-door surveys were implemented in most studies, 
where neurologists made diagnoses of epilepsy. Over 85% of deaths were estimated 
to be captured in these cohorts and verbal autopsy was used to diagnose causes of 
death. Most studies used an operational definition of epilepsy as defined by ILAE in 
the diagnosis of epilepsy, although studies of 3 populations were restricted to active 
convulsive epilepsies.29; 33; 35 
Clinical cohort studies were of low quality (≤50%), largely due to poor sample 
representativeness of the general population (Supporting Table 3). There was 
insufficient information published in most studies to determine the basis of the 
diagnosis of epilepsy.  Individuals in clinical cohorts often had epilepsy 
described as intractable or refractory.36; 38; 39 Cohorts of children with severe 
forms of epilepsy were also enrolled in several studies.37-40 In health care 
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settings, causes of death were available from medical records, death 
certificates, and verbal autopsy for deaths occurring in the communities. 
Mortality.  From 7 population-based studies with quality scores ≥80% (Table 1)7; 
8; 27; 30; 31; 34; 35, the median annual mortality rate was 19.8 deaths per 1000 
people with epilepsy (range 9.7-45.1), with a weighted median SMR of 2.6 
(range 1.3-7.2) and an overall CFR of 8.1% (range 3.3-31.6%). The weighted 
mean follow-up period was 5.8 years (range 1.5-10), with 6,665 person-years 
observation. 
 
Eight clinical cohorts (Table 2)12; 27; 36-41 in sum enrolled substantially larger numbers 
of people with epilepsy compared to higher-quality population-based studies. There 
were 3,856 people with epilepsy enrolled across these cohorts, of which 88.3% were 
followed to the end of the studies. The weighted mean follow-up period was 12.4 
years (range 3-30), during which 240 deaths were observed, with a pooled annual 
mortality rate of 7.1 (range 1.6-25.1) deaths per 1000 people with epilepsy. Two out 
of the 8 studies reported SMRs of 3.2 and 6.3.27; 37 The overall CFR in these clinical 
cohort studies was 5.4% (range 1.3-75.3 %). 
 Mortality risk by age.  Figure 2 summarizes 3 population-based studies reporting 
SMRs among people with epilepsy by age of death.27; 28; 33 Overall, these showed the 
highest SMRs in the youngest age groups, declining markedly after young 
adulthood, with a continuing decline with increasing age. We found insufficient data 
to characterize the risk of mortality by age of epilepsy onset.  
Mortality in lower-income countries 
Page 12 
 
Mortality risk by sex.  Figure S1 summarizes mortality estimates for males and 
females from 6 population-based studies and 6 clinical cohorts. Of five studies27; 28; 
31; 33; 35 comparing SMRs, two reported higher values among males, with a weighted 
median SMR of 5.0 for males compared to 4.5 for females (Supporting Figure 1, 
Panel A). Most studies reporting PMRs showed higher mortality in males than in 
females, with weighted medians of 62% and 38%, respectively (Supporting Figure 1, 
Panel B). 
Cause-specific mortality in epilepsy.  Table 3 presents 8 population-based studies 
that reported cause-specific proportional mortality rates in those with epilepsy.7; 27; 29; 
31-35 Among people with epilepsy, the weighted median PMR for all causes of death 
directly or indirectly attributable to epilepsy was 47%. Direct causes comprised 
status epilepticus (median PMR 13%), and possible or probable SUDEP (median 
PMR 13%; Supporting Table 4). Indirect causes included accidents (falls, road traffic, 
drowning, and burns; Supporting Table 5).  Among accidents, the median PMR was 
15% (range 3.3%-45%) for drowning,7; 28; 31-33 and 7.5% for road traffic accidents7; 28; 
33; 35; the remaining causes did not have sufficient data for a summary (Supporting 
Table 5). Among these population studies, the median sum of all listed accident-
related PMRs was 36% of all deaths in people with epilepsy. Other important causes 
of death in these populations that were not attributable to epilepsy included 
cerebrovascular diseases, tuberculosis, malaria, heart disease, and cancer 
(Supporting Table 6).  
Six clinical cohort studies reported causes of death as PMRs for individuals with 
epilepsy (Table 3).12; 27; 36-39 The median PMR for direct and indirect causes of death 
attributable to epilepsy was 39.3% and 24% respectively. Median PMRs for deaths 
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due to status epilepticus and SUDEP in clinical cohorts were 14.8% and 11.1% 
respectively (Supporting Table 4). Data regarding causes of death indirectly 
attributable to epilepsy and causes not attributable to epilepsy were not sufficiently 
large to enable generalization.  
Mortality risk by seizure type or frequency. Mortality risk by seizure (or epilepsy) type 
was reported from two population-based8; 34 and two clinical cohorts36; 41 in which 
median PMRs were consistently higher for focal epilepsy (population-based – 55% 
and clinical cohort – 73%) than for generalized epilepsy (population-based – 39% 
and clinical cohort – 26%; Supporting Table 7). Two studies reported increased 
mortality among people with epilepsy with a higher frequency of seizures31; 40 
(Supporting Table 8). 
Risk by duration of epilepsy.  Two studies reported on mortality by duration of 
epilepsy31; 35 (Supporting Table 9). A study in rural Kenya reported the highest 
mortality rate (45 per 1000 person-years) for people with epilepsy duration of <1 
year. In Uganda, SMRs were 8.6 (95% C.I. 4.5-16.5) for people with epilepsy of 
duration <5 years, 3.6 (1.1-11.4) for those of epilepsy duration 5-9 years, and 23.8 
(8.9-65.5) for those of epilepsy duration 10-14 years. 
Risk by epilepsy etiology.  Symptomatic epilepsies appeared to have higher mortality 
rates compared to cryptogenic epilepsy,8; 34; 36; 37 although only two studies provided 
direct comparisons34; 36 (Supporting Table 10). 
Risk by treatment adherence.  Five population-based studies reported mortality risk 
by treatment adherence,31-35 treatment allocation,32 time since last treatment,34 and 
dose allocation33 (Supporting Table 11). In Kenya, mortality rates were three times 
higher for individuals who did not adhere to AED treatment than for those who 
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adhered to treatment (mortality rate ratio 3.37,95% CI 1.84–6.16).35 In Uganda, the 
SMR was 7.4 (95%CI: 3.9—14.1) for those with self-reported good AED adherence 
compared to 8.0 (95% CI: 3.8—16.4) for those with poor adherence.31 In Cameroon, 
treatment with AEDs alone was associated with 14% of deaths compared to 27% in 
those using AEDs and traditional medicine.32 In one Chinese study, people receiving 
higher daily doses of phenobarbital (201-240 mg) had a lower mortality of 9% 
compared to those receiving medium doses (90-180 mg) with 44% mortality and low 
doses (30-90 mg) with mortality of 47%.33 In a Bolivian study, recent access to AEDs 
was associated with lower mortality than absence of treatment for an extended 
period.34  
Meta-analysis.  Meta-analysis revealed high heterogeneity across population-based 
studies as well as clinical cohort studies, and among high- and low-quality studies as 
well as short and long follow-up studies (Figures S2 and S3). Accordingly, a formal 
meta-analytic synthesis was not attempted.  
 
Discussion 
Summary findings. This study provides evidence of higher premature mortality in 
people with epilepsy than in the general populations of LMIC, based on systematic 
reviews of epidemiologic studies accrued over 25 years. The number of quality 
studies found is low—especially considering this length of time and the large majority 
of the world population residing in LMIC—and points to the need for much further 
research. Nevertheless, these limited studies indicate that the main causes of death 
in people with epilepsy in LMICs are those directly attributable to epilepsy, i.e. status 
epilepticus and sudden unexpected death in epilepsy, and indirectly related to 
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epilepsy, i.e. drowning, head injury, and burns. The burden of premature mortality 
related to epilepsy appears higher in LMIC than in HIC. Unmet healthcare needs and 
lack of capacity in managing seizures may be the main reasons for the mortality gap 
between HIC and LMIC. 
 
Interpretation.  Recognizing noteworthy earlier reviews of mortality associated with 
epilepsy specific to Africa11 and Latin America,42 our systematic review now 
examines a broader range of studies from LMIC across Africa, Asia, and South 
America.  The incidence of epilepsy varies substantially across regions comprising 
LMICs and is higher in regions with high incidence of encephalitis and meningitis and 
with endemic parasitic infections such as malaria and neurocysticercosis. The 
availability of basic public health services as well as specialized health care for 
epilepsy also varies considerably among LMICs.43 Both factors may strongly 
influence epilepsy-related mortality. Thus, any generalizations drawn from the 
modest number of studies we have reviewed should be applied to other LMIC 
regions with great caution. 
Despite their limitations, these data from LMIC provide clear evidence that the 
burden of premature mortality, as measured by SMRs, is higher among people with 
epilepsy than in corresponding general populations.  Among the regions 
represented, the risk of premature mortality in people with epilepsy is particularly 
high in Africa, where the reported annual mortality rates in population-based studies 
range from 22.2 to 45.1 per 1000 people with epilepsy,27; 30-32; 35 among which are 
reported SMRs of 6.5 and 7.2.31; 35 
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SMRs are especially high in children and young adults with epilepsy.  This finding 
might be explained in part by: (a) the comparatively lower mortality rates in general 
populations of young age, and (b) the increased mortality of recent-onset epilepsy  
associated with symptomatic or structural/metabolic etiologies, which occur with a 
substantial proportion of young cases.1  In HIC, higher SMRs have likewise been 
found in studies with age strata including children (range 6.4-8.5).13  Only one clinical 
cohort study in Ecuador27 reported an SMR (9.5) in a stratum similar to those of the 
HIC studies. Two other studies of lower quality from rural China reported extremely 
high SMR among children, but with wide confidence intervals.28; 33 
The burden of premature mortality among people with epilepsy in LMICs appears to 
be somewhat higher in males, as indicated by the PMRs from several studies. This 
could possibly reflect a higher incidence among males of symptomatic epilepsies 
(especially from traumatic brain injury), which have an increased mortality risk. In 
lower-income regions such as Africa, brain injuries commonly arise from vehicular 
collisions, occupational accidents, sports, and violence,44 which may be more 
frequent among males. The increased risk of premature mortality among males with 
epilepsy could also reflect mortality during hazardous occupations that carry an 
increased risk of drowning, falls, or other fatal injuries consequent to seizures.   
These data also indicate that among the most important causes of death are those 
directly related to epilepsy, in particular status epilepticus, previously recognized to 
have a high case fatality ratio in LMICs.45  The proportion of deaths from status 
epilepticus appears substantially higher in LMICs compared to HICs.13 This 
difference might be explained in part by better access to AED treatment, better 
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management of seizures, and better access to prompt treatment for prolonged 
seizures in HICs compared to LMICs.  
SUDEP was identified as another cause directly related to epilepsy in several LMIC 
studies.  The estimated proportions must, however, be viewed with caution as 
causes of death were seldom diagnosed through post-mortems and diagnoses of 
SUDEP made by verbal autopsy or clinical history may be inaccurate.18  
Nevertheless, many of the risk factors associated with SUDEP are more common in 
LMIC than in HIC, e.g., structural causes of the epilepsy and frequent seizures, and 
thus SUDEP may represent a greater burden in these regions than indicated by 
some studies. Specific studies to examine SUDEP occurrence in LMIC populations 
are needed.   
In comparison to HIC, a higher proportion of people with epilepsy in many LMIC 
regions also die due to indirect causes, especially accidents. Many of these causes, 
e.g. drowning and burns, are potentially preventable through education and safety 
measures. For other causes, e.g., seizure-caused fatal injuries incurred during work 
or while driving a vehicle, further studies are needed to understand the frequency 
and circumstances of these injuries and to identify appropriate prevention measures 
that are specific for different localities.  
Comparing Mortality in LMIC and HIC.  Overall, the relative premature mortality risk 
associated with epilepsy in LMIC appears higher than the risk reported in HICs. In 
the best quality LMIC studies, the weighted median SMR of 2.6 modestly exceeds 
the corresponding value of 2.2 in HIC.13  Such comparisons of SMRs between 
studies are, however, fraught with potential error,  especially given differing age 
distributions among study populations (with generally larger proportions of young 
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people in LMIC), problems with case finding (greater in LMIC), and differing overall 
mortality rates in the study base populations (usually higher in LMIC). Thus, the 
magnitude of the disparity suggested by SMRs may be deceptive and it appears 
likely that the actual burden of premature mortality with epilepsy, if this were 
measured as incidence rates in entire populations, would be much higher in LMIC.   
Implications. A limited number of studies demonstrate substantially elevated risks of 
premature mortality among people with epilepsy in LMIC of three continents.  Much 
of this may be attributed to the restricted distribution of healthcare resources in these 
countries, resources often far more limited than in HIC.43  Thus, lack of access and 
decreased adherence to medical management with AEDs place people with epilepsy 
at increased risk of fatal medical or injury-related complications of frequent seizures.  
Lack of access to prompt medical interventions for prolonged seizures places people 
with epilepsy at increased risk of death from status epilepticus. This mortality could 
be significantly reduced with improved access to health care including AEDs, and 
with education about the risks of epilepsy and ways to reduce these risks. In many 
communities, public education may be important to increase reliance on standard 
medical treatments of epilepsy as these are available, discourage its sole treatment 
by unproven folk medicine and traditional healing, and reduce its stigma,46-48  Also 
needed are improved public health and safety programs for primary prevention of 
structural causes of epilepsy—such as malaria, cysticercosis, and other infections of 
central nervous system—and accidents resulting in traumatic brain injuries. 
The limited existing data on epilepsy-related mortality in LMIC are, however, not 
sufficient for optimum development of prevention programs adapted to local needs.  
Too many countries and local regions are not described.  The circumstances of 
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fatalities from medical complications, e.g., status epilepticus, are uncertain.  What 
proportion are associated with no AED treatment and in what proportion is AED use 
interrupted or reduced because of inability to afford its cost?  The types and 
circumstances of fatal injuries arising from seizures are also uncertain.  Where do 
drownings in people with epilepsy occur, how many are occupational, and which 
occupations are involved?  How do fatal burns occur?  In how many traffic fatalities 
are pedestrians, vehicle passengers, or vehicle drivers individuals with epilepsy?  
How do local laws address motor vehicle driving by people with epilepsy?  How 
many injuries involve falls from heights and how many of these are occupational?  
How do risks vary according to local resources, customs, and industries (e.g., 
climbing trees for fruit picking)?  While current LMIC data on epilepsy mortality 
broadly indicate the urgency of prevention programs now, future research can 
improve such programs by providing answers to questions like those above. 
Limitations. There are substantial limitations to these data. The studies that met our 
inclusion criteria represented only a small number of communities in Sub-Saharan 
Africa, Asia, and South America, while other major regions of the world, such as 
North Africa and the Middle East, were entirely unrepresented. Under-representation 
of major regions may be associated with limitations of economic resources affecting 
their health care systems’ capacity to implement prevention programs, manage 
seizures in people with epilepsy and conduct epidemiological studies of mortality in 
epilepsy.  Health care systems and practices may also be affected independently by 
variations in regional culture, thus restricting our ability to generalize the findings 
from this review to unrepresented regions among LMIC. 
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The quality of the studies we reviewed varied considerably. The large heterogeneity 
observed illustrates the high degree of uncertainty in the estimation of the true 
occurrence of epilepsy-related mortality across LMICs. Incomplete ascertainment of 
epilepsy cases, a major concern in many of the studies, is likely to yield 
underestimates of the total burden of epilepsy mortality in general populations of 
LMIC. However, to the extent that studies over-represent more severe forms of 
epilepsy that carry higher risk of premature death, comparative measurements of 
mortality such as SMR could be increased.  Some population-based studies included 
only cases with convulsive epilepsies, while others may have incompletely 
ascertained cases with non-convulsive epilepsies. Most clinical cohorts over-
represented people with severe forms of epilepsy, such as one Brazilian study with 
72% of enrollees who reported daily seizures38 and another that enrolled people with 
refractory epilepsy awaiting or having undergone epilepsy surgery.36 The diagnosis 
of epilepsy in many studies was not made by clinicians with training in the diagnosis 
of epilepsy; thus the accuracy of the estimates and causes of death in epilepsy in 
some studies should be viewed with caution. Most of the causes of death were 
ascertained by review of clinical records or verbal autopsy. The accuracy of verbal 
autopsies varies depending on the other common causes of death in the population, 
the tool used, and the experience of the person administering the tool.23  As for post-
mortem examinations, while in HIC the proportion of deaths autopsied in general 
populations and in people with epilepsy can be low,49; 50 in comparison, none of the 
LMIC studies in this review included autopsy data. 
More epidemiological studies, involving more LMIC localities, are needed.  As with 
future studies in HIC, studies in LMIC should be performed in conformity with current 
guidelines for epidemiologic studies.15; 17  Representative population samples and 
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incident cohorts should be studied, where acute symptomatic seizures are 
distinguished from single unprovoked seizures and from epilepsy, and where 
convulsive and non-convulsive forms of epilepsy are also distinguished.  Finally, 
epileptogenic conditions and all risk factors implicated in the mortality of epilepsy 
should be clearly described. The collection of such higher quality information will 
enable us to identify many measures necessary to prevent much of the premature 
mortality in LMIC. 
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Table 1: Mortality estimates from population-based studies 
Populatio
n- based 
Country-
Location 
(Income) 
Total 
Population 
Quality 
People 
with 
epilepsy  
original 
cohort 
People 
with 
epilepsy 
followed 
up 
Duration 
of FU 
(years)* 
Estimated 
Person- 
years 
Deaths  SMR 95% CI CFR 95% CI 
Mortality 
rate per 
1000 
person-
year 
95% CI 
Ngugi 
2014 35 
Kenya-Rural 
(L) 
232,164 100 754 606 2.7 2,048 61 6.5 5.00-8.30 8.1 6.1-10 29.8 
22.8-
38.3 
Kochen 
20058 
Argentina-
Urban (M) 
70,000 90 106 96 8 768 8 2.45 1.14-4.65* 8.3 2.8-13.9 10.4 4.5-20.5 
Kaiser 
2007 31 
Uganda-
Rural (L) 
4,743 90 61 57 7 399 18 7.2 4.40-11.6 31.6 19.5-43.6 45.1 
26.7-
71.3 
Nicoletti 
200934 
Bolivia-Rural 
(M) 
55,675 85 118 103 10 1,030 10 1.34 0.68–2.39 9.7 4.0-15.4 9.7 4.7-17.9 
Houinato 
201330 
Benin-Rural 
(L) 
11,688 80 160 150 1.5 225 5   3.3 0.5-6.2 22.2 7.2-51.9 
Banerjee 
20107 
India-Urban 
(M) 
52,377 80 337 337 5 1,685 20 2.58 1.50-4.13 5.9 3.4-8.5 11.9 7.3-18.3 
Carpio 
200527 
India-Rural 
(Vusai) (M) 
16,000 80 51 51 10 510 10 3.9  19.6 8.7-30.5 19.6 9.4-36.1 
Summary: Higher quality 
population studies 
442,647  1,587 1,400 5.8† 6,665 132 2.6‡  8.1%‡  19.8 
16.7-
23.5 
               
Carpio 
200527 
India- Urban 
(Parsis) (M) 
14,010 65 109 104 14 1,456 34 0.76 0.51-1.01 32.7 
23.7-
41.7% 
23.4 
16.2-
32.6 
Kamgno 
200332 
Cameroon- 
Rural (L) 
NR 60 271 128 10 1,280 37   28.9 
21.1-
36.8% 
28.9 
20.4-
39.8 
Mu 2011 
33 
China-Rural 
(M) 
5,840,000 50 3,568 2,998 4.5 13,491 106 4.9 4.0-6.1 3.5 2.9-4.2% 7.9 6.4-9.5 
Ding 
201329§ 
China-Rural 
(M) 
3,185,000 50 2,455 1,986 6.1 12,114 206 2.9 2.6-3.4 10.4 9.0-11.7% 17.0 
14.8-
19.5 
Carpio 
200527 
Mali-
Urban/Rural 
(L) 
7,158 40 36 31 12 372 13   41.9 
24.6-
59.3% 
34.9 
18.8-
59.8 
Summary: Lower quality 
population studies 
>9,112,561  8,894 7,233 6.0† 32,850 431  2.9‡  10.4‡  13.1 
11.9-
14.4 
Key: FU: Follow-up, SMR: Standardized mortality ratio, CI: Confidence Interval, CFR: Case fatality ratio, (L): low-income country, (M): middle-income country 
*Length of follow-up described variously as median (Ngugi et al., 2014), mean (Ding et al., 2013), or the total interval of cohort assessment (others). 
†Mean weighted by study person-years 
‡Median weighted by study person-years 
§ Follow-up study of cohort described in Ding 200624.  
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Table 2: Mortality  estimates from clinical cohort studies 
 
 
Country-
Location 
Quality 
People with 
epilepsy in 
original cohort 
People with 
epilepsy 
followed  
Duration of 
follow up (years) 
Person-years Deaths SMR Case Fatality Ratio (%) 
Mortality rate per 
1000 person-year 
 95% CI  95% CI  95% CI 
Carpio 200527 
Ecuador- Urban 
(M) 50 420 379 3 1,137 7 6.3 2.0-10.0 1.8 0.5-3.2% 6.2 2.5-12.7 
Almeida 201036 
Brazil-
Urban/Rural 
(M) 45 550 550 10 5,500 16   2.9 1.5-4.3% 2.9 1.7-4.7 
Terra 201138 
Brazil-Urban 
(M) 35 1012 987 10 9,870 53   5.4 4.0-6.8% 5.4 4.0-7.0 
Jilek-Aall 199212 
Tanzania, Rural 
(L) 35 164 146 30 4,380 110   75.3 68.4-82.3% 25.1 20.6-30.3 
Thomas 200141 
India-Urban 
(M) 25 447 246 12 2,952 18   7.3 4.1-10.6% 6.1 3.6-9.6 
Terra 201039 
Brazil-Urban, 
Rural (M) 25 267 267 13 3,471 9   3.4 1.2-5.5% 2.6 1.2-4.0 
Devilat 200437 
Chile-
Urban/Rural 
(M) 5 NR NR 6 NR 16 3.21 1.5-5.0     
Terra 200940 
Brazil-Urban/ 
Rural (M) 5 996 835 8 6,680 11   1.3 0.5-2.1% 1.6 0.8-2.9 
Summary: all studies  3856 3410 12.4
† 33,990 240 4.8  5.4
‡  7.1 6.2-8.0 
Key: FU: Follow-up, SMR: Standardized mortality ratio, CI: Confidence Interval, CFR: Case fatality ratio, (L): low-income country, (M): middle-income country 
†Mean weighted by study person-years 
‡Median weighted by study person-years  
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Table 3: Estimates of proportional mortality in epilepsy by cause in population-based and clinical cohort studies 
Study Country-Location Design Quality 
Number of 
people with 
epilepsy 
followed 
Number 
of deaths 
Causes of death (%) 
Direct Indirect Unrelated Undetermined 
Ngugi 201435 Kenya-Rural Population 100% 606 61 44.3 11.4 34.3 9.8 
Kaiser 200731 Uganda-Rural Population 90% 61 18 33.0 17.0 44.4 5.6 
Nicoletti 200934 Bolivia-Rural Population 85% 103 10 10 20 50 20 
Banerjee 20107 India-Urban Population 80% 337 20 5 30 45 20 
Kamgno 200332 Cameroon-Rural Population 60% 271 37 75.5 10.8 13.7  
Mu 201133 China, Rural Population 50% 2,998 106 21.6 58.8 19.6  
Ding 201329 China, Rural Population 50% 1,986 206 14.1 32.5 39.3 14.1 
Carpio 200527 
Mali-Rural & 
Urban 
Population 40% 36 13 38.0 NR 62.0 NR 
Summary: all population-based   6,546 471 27.3* 20.0* 41.9* 14.1* 
Carpio 200527 Ecuador, Urban 
Clinical 
Cohort 
50% 379 7 42 30 28  
Almeida 201036 
Brazil, Urban-
Rural 
Clinical 
Cohort 
45% 550 16   62.5  
Terra 201138  Brazil, Urban Clinical 
Cohort 
35% 987 53 15.1  84.9  
Jilek-Aall 199212 Tanzania, Rural 
Clinical 
Cohort 
35% 164 110 17.3 18.2 32.7 31.8 
          
Terra 201039 
Brazil-Urban, 
Rural 
Clinical 
Cohort 
25% 267 9 77.8    
Devilat 200437 Chile, Santiago 
Clinical 
Cohort 
5% NR 16 39.3    
Summary: all clinical cohorts   >2,347 211 39.3* 24.1* 47.6*  
Key:  *Median percentage  
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Figure 1: Summary results of search strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Mortality in epilepsy by age at death 
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Supporting Information 
Supporting Table 1A.  Criteria and grading for assessing qualities of mortality studies 
Sensitivity of Epilepsy Case Ascertainment (20/20) 
 20/20 = Screening methods appear likely to ascertain nearly all (≥ 85%) cases in population 
 15/20 = Screening methods appear likely to ascertain most (70 - 84%) cases in population 
 10/20 = Screening methods appear likely to ascertain majority (50 - 69%) of cases in population 
 5/20 = Screening methods appear unlikely to ascertain majority of cases in population OR 
information published is insufficient to assess 
 0/20 N/A = Not applicable: not a population-based study or sensitivity of methods of epilepsy case 
ascertainment not relevant to quality of study. 
Sensitivity of Mortality Case Ascertainment (20/20) 
 20/20 = Fatalities appear likely to be recorded in nearly all (≥ 85%) cases in study population 
 15/20 = Fatalities appear likely to be recorded in most (70 - 84%) cases in study population 
 10/20 = Fatalities appear likely to be recorded in majority (50 - 69%) of cases in study population 
 5/20 = Fatalities appear unlikely to be recorded in majority of cases in study population OR 
information published is insufficient to assess 
Accuracy of Diagnoses of Epilepsy (20/20) 
 20/20 = Cases are diagnosed (or confirmed) by specialist  clinician (i.e., with neurologic training), 
AND ILAE case definition applied 
 15/20 = Cases are often diagnosed by non-specialist clinician, OR minor deviation from ILAE case 
definition 
 10/20 = All or substantial proportion of cases diagnosed based on self-report or non-clinical 
sources with specified criteria judged to have fair positive predictive value 
 5/20 = All or substantial proportion of cases diagnosed with poorly defined criteria from non-
clinical sources; positive predictive value judged to be poor OR information published is insufficient 
to assess 
Accuracy of Diagnoses of Cause of Death (20/20) 
 20/20 = Determined mainly from either autopsy, ME/coroner investigation, or other clinical 
investigation (e.g., review of medical records, structured interview of survivors or “verbal autopsy”) 
 15/20 = Determined largely or wholly from death certificate data, when such data are judged to 
have good positive predictive value for the specific causes of interest 
 10/20 = Determined largely or wholly from death certificate data, when such data are judged to 
have only fair positive predictive value for the specific causes of interest 
 5/20 = Other sources of data deemed to have poor positive predictive value for the causes of 
interest OR information published is insufficient to assess 
 0/20 = Cause of death not studied 
Representativeness of the study population (20/20) 
 20/20 = Cohort studies of incident epilepsy whose enrolled cases appear highly representative of 
the population of interest 
 15/20 = Studies of prevalent epilepsy whose enrolled cases appear highly representative of the 
population of interest 
 10/20 = Studies of epilepsy whose enrolled cases appear somewhat representative of the 
population of interest 
 5/20 = Studies of epilepsy whose enrolled cases appear poorly representative of the population of 
interest or where representativeness cannot be assessed. 
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Supporting Table 1B: Standard definition of epidemiological indicators of mortality in 
epilepsy 
Case fatality Ratio is the proportion of people with epilepsy in a cohort who die, usually 
expressed as a percentage. 
Proportionate mortality Rate (PMR) is the ratio of the number of deaths due to a specific 
cause in a population to the total number of deaths in the same period. 
 
Mortality rate in epilepsy is the number of deaths (all causes) in a population of individuals 
diagnosed with epilepsy people with epilepsy, and is calculated from number of deaths per 
person years of observation. 
 
Age-specific mortality fraction is the number of deaths in a given age group per time, 
usually expressed per 1,000 or 100,000 persons per year. 
 
Cause specific mortality rate is mortality rate from a specified cause for a population during 
a specified time period usually expressed per 1,000 or 100,000 persons per year. 
Standardized mortality ratio (SMR) is a ratio between the observed number of deaths in 
people with epilepsy and the number of deaths that would be expected, based on the age- 
and sex-specific rates in a standard population a. If the ratio of observed/expected deaths 
>is greater than 1.0, there is said to be "excess deaths" in the study population. With 
respect to the mortality in epilepsy, this measure is used to compare mortality in epilepsy 
with mortality in general population. 
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Supporting Table 2: Summary of characteristics and quality of population-based studies of mortality in epilepsy 
 
Key: DC Clinical Diagnosis; KI: Key informants, MR: Medical records, N/A: Not Available; NR Not Recorded;  PBS: Population-based screening, PHC: Primary health care, VA Verbal Autopsy, 
ILAE: International League Against Epilepsy 
*These studies describe the same cohort.  
†Convulsive epilepsy only. 
 
Study 
Country-
Location 
Dates Source 
Population 
(denominator) 
Epilepsy 
cases 
Case 
ascertainment 
% 
Diagnosis 
Mortality 
captured % 
Cause 
of Death 
Representativeness 
Overall Quality 
(Max 100) 
Kochen 
20058 
Argentina-
Urban 
1991-1998 PBS 70,000 106 ≥85 
ILAE by 
Neurologist 
≥85 DC Highly 90 
Houinato 
201330 
Benin- Rural 2006-2007 
PBS + 
MR+ KI 
11,688 160 ≥85 
ILAE by 
Neurologist 
≥85 N/A Highly 80 
Nicoletti 
200934 
Bolivia-Rural 1994-2004 PBS 55,675 118 ≥85 ILAE ≥85 NR Highly 85 
Kamgno 
200332 
Cameroon- 
Rural 
1991-2001 KI NR 271 50-69 
ILAE by 
Physicians 
70-84 NR Somewhat 60 
Ding 
200628 
China-Rural 2000-2004 PHC 3,185,000 2455† N/A NR 70-84 VA Somewhat 50 
Mu 
201133 
China-Rural  PHC 5,840,000 3568† N/A NR 70-84 VA Somewhat 50 
Ding 
201329 
China-Rural 2000-2008 PHC 3,185,000 2455† N/A NR 70-84 VA+DC Somewhat 50 
Carpio 
200527 
India- Rural 1985-1999 PBS 14,010 109 ≥85 Neurologist ≥85 N/A Poorly 65 
Banerjee 
20107 
India- Urban 2003-2005 PBS 52,377 337 ≥85 
ILAE by 
Neurologist 
≥85 N/A Highly 80 
Carpio 
200527 
India- Urban 1989-1994 PBS 16,000 51† ≥85 NR ≥85 VA Somewhat 80 
Ngugi 
201430 
Kenya- Rural 2007-2010 PBS 232,164 754† ≥85% 
ILAE by 
Neurologist 
≥85 VA Highly 100 
Carpio 
200527 
Mali-Urban, 
Rural 
1988-2000 KI 7,158 36† 50 - 69 NR 70-84 NR Poorly 40 
Kaiser 
200731 
Uganda- Rural 1994-2001 PBS 4,743 61 ≥85 ILAE ≥85 VA Somewhat 90 
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Supporting Table 3: Summary of characteristics and quality of clinical cohort studies of mortality in epilepsy 
 
 
Key: N/A – Not Available; N/R – Not recorded, ILAE- International League Against Epilepsy 
 
 
 
 
Study 
Country-
Location 
Dates 
Source of clinical 
cohort 
Epilepsy 
cases 
Case Diagnosis Mortality 
Cause 
of Death 
Representativeness 
Overall Quality 
(Max 100) 
Carpio 200527 Ecuador-Urban 1997-2000 Tertiary Hospital 420 N/A ILAE ≥85 N/A Somewhat 50 
Almeilda 201036 Brazil-Both 1992-2002 Tertiary Hospital 550 N/A Clinical ≥85 N/A Poor 45 
Terra 201138 Brazil-Urban 2000-2010 Tertiary Hospital 1012 N/A N/R ≥85 SR Poor 35 
Jilek-Aall 199212 Tanzania-Rural 1960-1990 District Hospital 164 N/A N/R ≥85 N/A Somewhat 35 
Thomas 200141 India-Urban 1985-1997 Tertiary Hospital 447 N/A N/R 50 - 69 N/A Somewhat 25 
Terra 201039 Brazil-Both 1995-2008 Tertiary Hospital 267 N/A N/R > 80 N/I Poor 25 
Terra 200940 Brazil-Both 2000-2008 Tertiary Hospital 996 N/A N/R N/R N/I Poor 5 
Devilat 200437 Chile-Both 1996-2002 Tertiary Hospital  N/A N/R N/R N/I Poor 5 
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Supporting Table 4: Estimates of proportionate mortality ratio (PRM) from SUDEP and status epilepticus among people with epilepsy 
   PMR in % 
Study Country-Location Quality SUDEP SE 
Population based studies 
Ngugi 201435 Kenya-Rural 100 6.6a 37.7a 
Kaiser 200731 Uganda-Rural 90 11.1 22.2 
Carpio 200527 India-Urban-Vasai 80 20 a  
Nicoletti 200934 Bolivia-Rural 85  10 
Banerjee 20107 India-Urban 80  5 
Kamgno 200332 Cameroon-Rural 60 18.9 56.6 
Mu 201133 China, Rural 50 14.7b 6.9 
Ding 201329 China, Rural 50 1b 13.1 
Median All Population Studies  12.9 13.1 
Clinical cohort studies 
Carpio 200527 Ecuador, Urban 50 14.3 c 23 
   28.6 b  
Almeida 201036 Brazil, Urban-Rural 45 2.9 b  
Terra 201138 Brazil, Urban 35 13.2 15.1 
Jilek-Aall 199212 Tanzania, Rural 35  14.5 
Terra 201039 Brazil, Urban-Rural 25 11.1  
Devilat 200437 Chile-Santiago 5 31.25 b  
 Urban/Rural  6.25 c  
Terra 200940 Brazil-Urban, Rural 5 1.38  
Median All clinical cohorts  11.1 14.8 
Key: PMR: Proportionate mortality ratio, SUDEP: Sudden death in epilepsy, SE: Status epilepticus 
aCases described as possible. 
bCases described as probable. 
cCases described as definite. 
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Supporting Table 5: Estimates of proportionate mortality ratio (PMR) in epilepsy by type of injury 
    
PMR by type of injury 
Study Country-
Location 
Quality Falls Drowning Traffic 
injury 
Burns Suicide 
Population based studies 
Ngugi 201435 Kenya-Rural 100 3.3 3.3 1.6 1.6 
 
Kaiser 200731 Uganda-Rural 90 
 
5.6 
 
11.1 
 
Nicoletti 
200934 
Bolivia-Rural 85   10  10 
Banerjee 
20107 
India-Urban 80  15 15   
Kamgno 
200332 
Cameroon-Rural 60 
 
10.8 
   
Ding 200628 China, Rural 50 
 
37 
 
2.9 
  
Mu 201133 China, Rural 50 5.9 45.1 4.9 
 
2.9 
Clinical cohort studies 
Terra 201138 Brazil, Urban 35 1.9 1.9 
   
Jilek-Aall 
199212 
Tanzania, Rural 35 
 
12.7 
 
5.5 
 
Key: PMR: Proportionate mortality ratio 
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Supporting Table 6: Estimates of causes of death reported in SMR and MR 
Study 
Country-
Location 
Quality Measure Causes Estimate (95% C.I.) 
Mu 201133 China, Rural 50 SMR 
Cerebrovascular 1.14 (0.36–3.61) 
Cardiac disease 1.60 (0.50–5.22) 
Influenza and 
pneumonia 
1.05 (0.26–4.32) 
Malignant 
neoplasm 
1.94 (0.90–4.18) 
Other diseases 11.41 (4.03–32.43) 
Ding 
201329 
 
China, Rural 
 
50 
 
SMR 
 
Drowning 39.0 (26.4–55.5) 
Toxic effects 17.0 (6.9–35.7) 
Falls 9.8 (3.6–21.7) 
Suicide 8.2 (4.5–14.0) 
Transport injury 6.0 (2.8–11.4) 
Myocardial 
infarction 
3.6 (1.6–7.2) 
Digestive system 
diseases 
4.4 (2.3–7.7) 
Pneumonia 2.9 (0.7–7.8) 
Cerebrovascular 2.2 (1.5–3.1) 
Neoplasms 1.1 (0.7–1.8) 
Terra 
200940 
Brazil, 
Urban-Rural 
5 MR 
Unrelated to 
epilepsy 
22.2 
Key: SMR-Standardized mortality ratio, MR-Mortality rate, CI-Confidence interval 
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Supporting Table 7: Proportionate Mortality Ratio (PMR%) by Type of Seizure 
  
 
 
PMR for epilepsy type 
Study Location Source Quality Generalized  Focal Unknown 
Kochen 20058 Argentina-Urban Population 90 37.5 50 12.5 
Nicoletti 200934 Bolivia-Rural Population 85 40 60  
Almeida 201036 Brazil, Urban-Rural Clinical Cohort 45 14.3 85.7  
Thomas 200141 India, Urban Clinical Cohort 25 38.9 61.1 
 
Key: PMR-Proportionate mortality ratio 
 
 
Supporting Table 8: Estimates of mortality in epilepsy by seizure frequency 
Study Location Source Quality Measure Frequency SMR/MR 
Kaiser 
200731 
Uganda-Rural Population 90 SMR 
High  
(>1 per 
week) 
14.7  
(8.5—24.8) 
Low  
(<1 per 
week) 
1.4  
(0.4—5.7) 
Terra 
200940 
Brazil- 
Urban/Rural 
Cohort 5 MR 
Daily 0.63 
2-4 per 
week 0.50 
1 per 
month 0.13 
Key: SMR-Standardized mortality ratio, MR-Mortality rate 
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Supporting Table 9: Estimates of mortality in epilepsy by duration of epilepsy in population-based studies 
Study 
Country-
Location Quality Measure 
Duration of 
epilepsy (years) MR/SMR 
Ngugi 201435 Kenya-Rural 100 MR 
<1 45.9(22.9–91.7) 
1–5 30.8(19.1–49.5) 
6–10 35.9(20.4–63.2) 
>10 31.1(20.9–46.4) 
Kaiser 
200731 
Uganda-
Rural 
90 SMR 
0-4 8.6 (4.5-16.5) 
5-9 3.6 (1.1-11.4) 
10-14 23.8 (8.9-65.5) 
Key: SMR-Standardized mortality ratio, MR-Mortality rate 
 
Supporting Table 10: Estimates of proportionate mortality ratios (PMR) in epilepsy by etiology 
    
Etiology 
Study 
Country-
Location 
Quality Measure Cryptogenic Symptomatic 
Remote 
seizure 
Undetermined 
Almeida 
201036 
Brazil, Urban-
Rural 
45 PMR 21.4 78.6   
Devilat 200437 
Chile-
Urban/Rural 
5 PMR  81.3   
Kochen 20058 
Argentina-
Urban 
95 PMR   75 25 
Nicoletti 
200934 
Bolivia-Rural 85 
PMR   60  
SMR 
0.74 
(0.2–1.8)* 
 3 
(1.2–6.3) 
 
Key: PMR-Proportionate mortality rate, SMR-Standardized mortality rate 
* Idiopathic 
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Supporting Table 11: Estimates of mortality in epilepsy by treatment 
Study 
Country-
Location 
Quality Measure Treatment Result 
Ngugi 
201435 
Kenya-Rural 100 MR 
Adherence 16.1 (9.5–27.2) 
Non adherence 48.8 (36.7–65.0) 
Kaiser 
200731 
Uganda-Rural 90 SMR 
Good adherence 7.4 
Poor adherence 8.0 
Kamgno 
200332 
Cameroon-
Rural 
60 PMR 
AED 13.6 
AED + Traditional 27.3 
Mu 201133 China, Rural 50 PMR 
Phenobarbital 
Dose: 30–60 mg. 47.2 
Phenobarbital 
Dose: 90–180 mg. 44.3 
Phenobarbital 
Dose: 210–240 mg. 8.5 
Nicoletti 
200934 
Bolivia-Rural  PMR 
Treatment in past year 20 
No treatment in past year 80 
Treatment in last month 20 
No treatment in last 
month 
80 
Key: AED-Antiepileptic drug, MR-Mortality rate, SMR-Standardized mortality ratio, PMR-Proportionate mortality ratio 
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Supporting Figure 1: SMR and PMR of epilepsy by sex 
 
 
 
 
 
 
 
 
 
 
 
 
Note: P=Parsis, V=Vusai  
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Supporting Figure 2: Forest plot of excess mortality in epilepsy by quality of studies 
 
 
Key: CI-Confidence interval, V-Vusai, P-Parsis, M-Mali, E-Ecuador  
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Supporting Figure 3: Forest plot of excess mortality in epilepsy by duration of cohort 
follow-up 
 
 
Key: CI-Confidence interval, V-Vusai, P-Parsis, M-Mali, E-Ecuador 
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